Pharmaceutical Resource Technology, Inc. Filed Primary

What the company does

Pharmaceutical Resource Technology, Inc. is a Wyoming corporation that manufactures dietary health supplements, skin care products, and honey straws in Singapore, selling these products through online portals and distributors throughout the Asia region. The company also operates a building and construction business in Singapore that provides new building design and construction, interior design and renovation, and alteration and addition of existing buildings and structures. The company conducts substantially all of its operations through a related-party arrangement with Superbee Network Singapore Pte. Ltd. and has only two permanent employees.

Use of proceeds

The company estimates net proceeds of approximately $50,000,000 if all shares are sold, and intends to use the proceeds primarily to support the expansion of its honey straw and pharmaceutical and dietary supplements manufacturing operations, including increasing production capacity, establishing or expanding manufacturing facilities in new geographic markets, and acquiring additional machinery and equipment. A portion of the proceeds will also be used for general corporate purposes, including working capital, operating expenses, and costs associated with maintaining its status as a public company.

Underwriters

The completed effective-prospectus read stated no underwriters.

Extracted from S-1/A 0001477932-26-003701, filed Jun 9, 2026 and verified against that filing text.

Key risk factors

• Dependence on Superbee Network Singapore

  “We are highly dependent on third-party service providers and management arrangements to conduct our operations.”

• Geographically concentrated operations

  “Our business operations are geographically concentrated outside the United States.”

• Officer and director control

  “Our officers and directors exercise significant control over the Company.”

• Immediate and substantial dilution

  “Investors in this offering will experience immediate and substantial dilution.”

• No public market for common stock

  “There is no public market for our common stock, and a market may never develop.”

• Limited number of direct employees

  “We have a very limited number of direct employees and rely extensively on outsourced staffing.”

• Self-underwritten best-efforts offering

  “This is a best-efforts, self-underwritten offering, and there is no assurance that we will be able to sell any shares.”

• Arbitrarily determined offering price

  “The offering price of our common stock was arbitrarily determined and is not based on traditional valuation metrics.”